MOR 208

Drug Profile

MOR 208

Alternative Names: anti-CD19 MAb XmAb5574; anti-CD19 MoAb XmAb5574; MOR-00208; MOR-208; XENP-5574; XmAb-5574

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xencor
  • Developer MorphoSys; The Ohio State University Comprehensive Cancer Center; Xencor
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diffuse large B cell lymphoma
  • Phase II Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 06 Nov 2017 Ohio State University Comprehensive Cancer Center and MorphoSys terminates a phase II trial in Chronic lymphocytic leukaemia (combination therapy, second-line therapy or greater) in USA for participant recruitment, due to internal data analysis (IV) (NCT02005289)
  • 23 Oct 2017 MOR 208 receives Breakthrough Therapy status for Diffuse large B cell lymphoma (Combination therapy) in USA
  • 22 Jun 2017 Efficacy and safety data from a phase II trial in Acute lymphoblastic leukaemia were presented at the 22nd Congress of the European Haematology Association (EHA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top